Sign In
to Vote &
Create Storyboards.
 

First treatment for infants with CAPS licensed in UK

Medical News Today - 20 Dec 2013 12:00
Anakinra (Kineret®), an interleukin-1 (IL-1) inhibitor, has been granted a licence for treatment of CAPS in children and adults by the Medicines and Healthcare Products Regulatory Agency (MHRA). Anakinra is the first CAPS treatment licensed for use in children as young as eight months. CAPS is an umbrella term for a number of ultra-rare, life-long, severely debilitating autoinflammatory diseases which cause rash, headache, fever, joint pain and other inflammatory symptoms. CAPS affects approxim...
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard